<DOC>
	<DOCNO>NCT02866747</DOCNO>
	<brief_summary>This study phase I/II , national , multicenter , open-label study start Phase I part follow Phase II part . The phase I part study aim evaluate safety association hypofractionated stereotactic radiation therapy ( hFSRT ) anti-PD-L1 Durvalumab immunotherapy patient recurrent glioblastoma . A maximum number 12 patient enrolled phase I part . Once recommended combination schema declare , patient enrol Phase II part study order evaluate efficacy ( local control rate ) combine treatment recurrent glioblastoma . In Phase II part , patient assign randomization one two follow arm : - Arm A ( control arm ) : Radiation therapy alone ( 17 patient ) - Arm B ( Experimental arm ) : Combined treatment Anti-PD-L1 Durvalumab ( 33 patient )</brief_summary>
	<brief_title>A Study Evaluating Association Hypofractionated Stereotactic Radiation Therapy Durvalumab Patients With Recurrent Glioblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age ≥ 18 year time study entry . 2 . Previous histopathologic confirmation glioblastoma . 3 . Any line recurrence glioblastoma prove contrast enhance Magnetic Resonance Imaging ( MRI ) within 28 day prior first fraction radiotherapy ( RT ) , per modify Response Assessment NeuroOncology ( RANO ) criterion . Note : Recurrence define progression follow therapy ( i.e. , chemotherapy , radiation , second surgery ) . 4 . Recurrent nodule histologically confirm diagnosis World Health Organization ( WHO ) Grade IV malignant glioma ( Glioblastoma ) occur previous irradiation field . 5 . Recurrent disease document MRI evidence size recurrence evaluate T1 postgadolinium sequence ≤35mm . 6 . Patient reirradiation ( hFSRT ) decide multidisciplinary medical board . 7 . Patients measurable disease . 8 . Prior radiotherapy must end least 12 week first fraction RT ( unless progressive disease outside radiation field histopathologic confirmation unequivocal tumor eliminate pseudoprogression image accord RANO recommendation ) . 9 . In case previous antiVascular Endothelial Growth Factor ( VEGF ) /Vascular Endothelial Growth Factor Receptor ( VEGFR ) target therapy : least 28 day last injection antiVEGF/VEGFR target therapy first fraction RT . 10 . Karnofsky performance status ≥70 . 11 . Adequate hematologic , renal hepatic function , define : Absolute Neutrophil Count ≥ 1500/mm3 Haemoglobin ≥ 9.0 g/dL Platelet count ≥ 100,000/mm3 Total bilirubin ≤ 1.5 x Upper Limit Normal ( ULN ) ( patient confirm Gilbert 's syndrome , Total bilirubin ≤ 3 x ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN Creatinine ≤ 1.5 x ULN creatinine clearance ( CrCl ) ≥ 40 mL/min , use CockcroftGault formula : Female CrCl = ( 140 age year ) x weight kilogram ( kg ) x 0.85 /72 x serum creatinine milligram/deciliter ( mg/dL ) Male CrCl = ( 140 age year ) x weight kg x 1.00/72 x serum creatinine mg/dL 12 . Female Patients must either nonreproductive potential ( i.e. , postmenopausal history : ≥60 year old menses ≥1 year without alternative medical cause ; history hysterectomy , history bilateral tubal ligation , history bilateral oophorectomy ) must negative serum pregnancy test upon study entry . 13 . Written inform consent locally require authorization ( e.g. , Social security France ( Health Insurance ) ) obtain patient prior perform protocolrelated procedure , include screen evaluation . 14 . Patient willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . 1 . Multifocal glioblastoma multiforme ( GBM ) recurrence . 2 . Distance tumor optic way include chiasma brainstem &lt; 1 cm . 3 . Prior reirradiation . 4 . Prior exposure Durvalumab antiProgrammed cell death 1 ( PD1 ) , antiProgrammed deathligand 1 ( PDL1 ) , anticytotoxic Tlymphocyteassociated protein 4 ( CTLA4 ) antibody . 5 . Patient receive live vaccine within 30 day prior first fraction RT . 6 . Receipt last dose anticancer therapy ( chemotherapy , immunotherapy , endocrine therapy , target therapy , biologic therapy , tumor embolization , monoclonal antibody , investigational agent ) within 28 day prior first fraction RT . 7 . Current prior use immunosuppressive medication within 28 day first fraction RT ( exception : systemic corticosteroid physiologic dos exceed 10 mg/day prednisone equivalent allow well steroids premedication hypersensitivity reaction ( eg , CT scan premedication ) Topical , inhale , nasal ophthalmic steroid prohibit ) . 8 . Mean QT interval correct heart rate ( QTc ) ≥470 m calculate 3 electrocardiogram ( ECGs ) use Fridericia 's Correction 9 . Presence diffuse leptomeningeal disease extracranial disease . 10 . Active suspect prior document autoimmune disease ( include inflammatory bowel disease , celiac disease , irritable bowel syndrome , Wegener 's granulomatosis Hashimoto 's thyroiditis ) . Note : participant vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger , permit enroll . 11 . Known primary immunodeficiency active Human Immunodeficiency Virus ( HIV ) . 12 . Known active chronic viral hepatitis history type hepatitis within last 6 month indicate positive test hepatitis B surface antigen ( HBV sAG ) hepatitis C virus antibody . 13 . History organ transplant require use immunosuppressive medication . 14 . History active tuberculosis . 15 . Current pneumonitis interstitial lung disease . 16 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrhythmia , active peptic ulcer disease gastritis , active bleeding diatheses . 17 . Other invasive malignancy within 2 year prior entry study , except treated surgical therapy . 18 . History severe allergic reaction unknown allergen component study drug . 19 . Any prior Grade ≥ 3 immunerelated adverse event ( irAE ) prior corticosteroidrefractory irAE . 20 . Participation clinical trial involve another investigational product within 4 week prior first fraction RT . 21 . Participation clinical trial deliver dose &gt; 60 Gy primotreatment glioblastoma . 22 . Female patient pregnant , breastfeed male female patient reproductive potential employ highly effective method birth control . 23 . Any condition , clinical judgment investigator , likely prevent patient comply aspect protocol may put patient unacceptable risk . 24 . Mental impairment ( psychiatric illness/social situation ) may compromise ability patient give inform consent comply requirement study . 25 . Patient forfeit his/her freedom administrative legal award guardianship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>